Outset Medical will present at the 2024 Stifel Healthcare conference on November 19, highlighting its innovative dialysis technology.
Quiver AI Summary
Outset Medical, Inc., a medical technology company focused on innovating dialysis solutions, announced that its management will present at the 2024 Stifel Healthcare conference on November 19, 2024, at 10:20 a.m. Eastern time. The presentation will be accessible via a live and archived webcast on the company's website. Outset's flagship product, the Tablo® Hemodialysis System, is designed to lower the costs and complexities associated with dialysis and is FDA cleared for use in both hospital and home settings. Tablo simplifies dialysis for providers while enhancing the patient experience, functioning as a comprehensive solution with integrated water purification and on-demand dialysate production, facilitating treatment delivery in various environments along with advanced data management capabilities.
Potential Positives
- Outset Medical will present at the prestigious 2024 Stifel Healthcare conference, enhancing visibility and credibility within the healthcare sector.
- The company’s innovative Tablo® Hemodialysis System represents a significant technological advancement in dialysis, potentially attracting interest from investors and healthcare providers.
- The FDA clearance for the Tablo system for both hospital and home use expands its market potential and demonstrates regulatory confidence in the technology.
- Tablo's integration of technology, such as water purification and on-demand dialysate production, positions Outset as a leader in simplifying dialysis care, which could improve patient outcomes and provider efficiency.
Potential Negatives
- None
FAQ
When is Outset Medical's presentation at the Stifel Healthcare conference?
The presentation is scheduled for Tuesday, November 19, 2024, at 10:20 a.m. Eastern time.
Where can I watch the Outset Medical conference presentation?
A live and archived webcast will be available on the "Investors" section of the Outset website.
What technology does Outset Medical offer for dialysis?
Outset Medical offers the Tablo® Hemodialysis System, designed to reduce the cost and complexity of dialysis.
How does the Tablo system improve dialysis care?
Tablo integrates water purification with on-demand dialysate production, enabling dialysis to be delivered anytime and anywhere.
Is the Tablo Hemodialysis System FDA certified?
Yes, the Tablo Hemodialysis System is FDA cleared for use from the hospital to the home.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OM Insider Trading Activity
$OM insiders have traded $OM stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $OM stock by insiders over the last 6 months:
- JOHN L. BROTTEM (General Counsel) has traded it 2 times. They made 0 purchases and 2 sales, selling 13,580 shares.
- LESLIE TRIGG (Chair and CEO) sold 5,308 shares.
- MARC NASH (SVP Operations and R&D) has traded it 2 times. They made 0 purchases and 2 sales, selling 2,016 shares.
- NABEEL AHMED (Chief Financial Officer) sold 3,971 shares.
- D KEITH GROSSMAN has traded it 2 times. They made 0 purchases and 2 sales, selling 38,117 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OM Hedge Fund Activity
We have seen 39 institutional investors add shares of $OM stock to their portfolio, and 93 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMERIPRISE FINANCIAL INC removed 3,389,927 shares (-65.2%) from their portfolio in Q3 2024
- JPMORGAN CHASE & CO removed 3,057,774 shares (-99.5%) from their portfolio in Q3 2024
- FMR LLC removed 2,923,144 shares (-38.0%) from their portfolio in Q3 2024
- BRAIDWELL LP removed 1,705,902 shares (-71.1%) from their portfolio in Q2 2024
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 1,538,859 shares (-100.0%) from their portfolio in Q3 2024
- GMT CAPITAL CORP added 1,471,706 shares (+inf%) to their portfolio in Q2 2024
- ASSENAGON ASSET MANAGEMENT S.A. removed 1,117,507 shares (-73.8%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN JOSE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 2024 Stifel Healthcare conference on Tuesday, November 19, 2024, at 10:20 a.m. Eastern time.
A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/ .
About Outset Medical, Inc.
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
Contact
Jim Mazzola
Investor Relations
[email protected]
